medizinonline.ch

Anrufen Wegbeschreibung Website

medizinonline.ch Das medizinische Fachportal für CME-Fortbildungen für Ärzte, News und Kongress-Updates Medizinonline.com ist ein Fach- und Fortbildungsportal für Ärzte.

Es liefert hochqualitative und aktuelle Meldungen aus allen wichtigen Fachbereichen der Medizin und basiert auf den Beiträgen von ca. 200 medizinischen Fachexperten und Key-Opinion-Leadern aus ihren jeweiligen Forschungsbereichen. Als registrierte Fachperson haben Sie jederzeit und überall Zugriff auf die gesamten Inhalte der PPM MEDIC-Printprodukte und Einiges mehr:
Machen Sie ihre CME-Fort- und Weiterbildung online, auf Ihrem Tablet oder Smartphone. Sie haben jederzeit Zugang zu Berichterstattung von den wichtigsten internationalen und europäischen Kongresse, News aus Medizin, Pharma und Gesundheitspolitik.

CONGRESS ANNOUNCEMENTIFAS 2026, the trade fair for the Swiss healthcare market, will take place at Messe Zürich from 20-...
07/10/2026

CONGRESS ANNOUNCEMENT

IFAS 2026, the trade fair for the Swiss healthcare market, will take place at Messe Zürich from 20-23 October 2026.

Held every two years since 1976, IFAS brings more than 400 exhibitors and around 16,000 attendees together from across the Swiss healthcare value chain, covering medical technology, IT and digital health, nursing and hygiene, laboratory diagnostics and physiotherapy.

Alongside the exhibition floor there are expert forums with lectures and panel discussions, a speakers corner, a startup park and a job fair for the health professions.

A key date for the healthcare sector in Switzerland.

Find out more here:

IFAS 2026 takes place October 20-23, 2022 in Zürich, Switzerland. Organized by IFAS. Register now.

RHEUMATOLOGY UPDATEDoes inflammation carry the same cardiovascular risk in every patient with rheumatoid arthritis?Persi...
05/10/2026

RHEUMATOLOGY UPDATE

Does inflammation carry the same cardiovascular risk in every patient with rheumatoid arthritis?

Persistent disease activity is associated with atherosclerosis and cardiovascular events, but an analysis of 4,008 patients from the international ATACC-RA cohort suggests the relationship depends on s*x and ACPA status.

In ACPA-negative patients, each one-point rise in DAS28-CRP was associated with a higher risk of major adverse cardiovascular events in men, but not in women. In ACPA-positive women, it was ACPA positivity rather than disease activity that carried the association.

Read the full article on MedizinOnline:

Persistent disease activity and cumulative inflammation in rheumatoid arthritis (RA) are associated with the progression of atherosclerosis and cardiovascular

CONGRESS ANNOUNCEMENT The 44th Congress of the ESCRS, the European Society of Cataract and Refractive Surgeons, will tak...
02/10/2026

CONGRESS ANNOUNCEMENT

The 44th Congress of the ESCRS, the European Society of Cataract and Refractive Surgeons, will take place next week at ExCeL London from 11–15 September 2026.

The congress gathers ophthalmologists and eye-care professionals from around the world for symposia, instructional courses, wet labs and live surgical sessions covering the latest advances in cataract, refractive and corneal surgery.

A key meeting for the ophthalmology community in Europe and beyond.

Find out more here: https://congressagenda.com/congress/escrs-2026

CME OPPORTUNITYDoes a multidrug-resistant pathogen in a wound call for strict isolation?Often not. Multidrug resistance ...
02/10/2026

CME OPPORTUNITY

Does a multidrug-resistant pathogen in a wound call for strict isolation?

Often not. Multidrug resistance applies to antibiotics, not to antiseptics or hand and surface disinfectants, so the measures that matter most remain effective.

This CME article covers the pathogens involved, from MRSA and VRE to Pseudomonas and Acinetobacter, diagnostics and swab technique, antiseptic and systemic treatment, and the risk assessment behind functional isolation.

Read the full CME article on MedizinOnline:

Patients whose wounds are colonized by multidrug-resistant pathogens (MDR) pose a particular challenge for infection prevention. In hospitals and long-term

CONGRESS REPORTWhat changed in severe asthma several years ago is now reaching COPD: targeted, phenotype-specific antibo...
30/09/2026

CONGRESS REPORT

What changed in severe asthma several years ago is now reaching COPD: targeted, phenotype-specific antibody therapy.

Dupilumab and mepolizumab have both received Swissmedic approval for COPD. They are add-on options for exacerbation-prone patients with eosinophilic disease that remains uncontrolled on triple therapy.

At the KHM Congress in Lucerne, Dr Alexander Turk set out how blood eosinophil counts guide that decision, and made the point that biologics complement the rest of the treatment plan rather than replace it.

Read the full MedizinOnline congress report:

What led to a paradigm shift in severe asthma several years ago is now also making its way into COPD treatment: targeted, phenotype-specific antibody therapy.

PNEUMOLOGY UPDATEHow many blood eosinophil measurements are needed to identify the eosinophilic COPD phenotype?Between 2...
28/09/2026

PNEUMOLOGY UPDATE

How many blood eosinophil measurements are needed to identify the eosinophilic COPD phenotype?

Between 20 and 40% of COPD patients show type 2 inflammation, associated with more frequent exacerbations and a favourable response to inhaled corticosteroids and biologics. Counts fluctuate considerably over time.

A simulation across 11 cohorts found that a single measurement detected intermittent eosinophilia in 42.9% of cases, while three measurements at baseline, 6 and 12 months reached 81.4%.

Read the full article on MedizinOnline:

Approximately 20–40% of all COPD patients exhibit Type 2 inflammation, which is characterized by elevated BEC. This eosinophilic phenotype is associated with

CME OPPORTUNITYWhich patients benefit from spinal cord stimulation, and on what evidence?Spinal cord stimulation is amon...
25/09/2026

CME OPPORTUNITY

Which patients benefit from spinal cord stimulation, and on what evidence?

Spinal cord stimulation is among the most technologically advanced and best-evaluated interventional approaches in modern medicine, with a therapeutic range that is often underestimated.

This CME article covers the neurophysiological basis, from gate-control theory to the nerve fibre types involved, and distinguishes the two indication areas: chronic neuropathic pain, and vascular indications including peripheral arterial disease at Fontaine stages IIb and III and refractory angina. It also looks at closed-loop systems with ECAP measurement, implantation technique, and safety data from the European registry.

Spinal cord stimulation (SCS ) is currently one of the most technologically advanced and scientifically well-evaluated interventional approaches in modern

CONGRESS ANNOUNCEMENTMSToronto 2026, the 10th Joint ACTRIMS-ECTRIMS Global Meeting, will take place at the Metro Toronto...
23/09/2026

CONGRESS ANNOUNCEMENT

MSToronto 2026, the 10th Joint ACTRIMS-ECTRIMS Global Meeting, will take place at the Metro Toronto Convention Centre from 21-24 October 2026, with an online option.

Held every three years, the joint meeting of the American and European MS committees is the largest congress dedicated to multiple sclerosis and related neuroinflammatory disorders, drawing more than 9,000 attendees from over 100 countries.

The programme spans progressive and paediatric MS, neuroimaging, biomarkers, remyelination and clinical trials, through keynote lectures, scientific and educational sessions, late-breaking abstracts and posters. CME/CPD credits are available through EACCME and ACCME.

MSToronto 2026 10th Joint ACTRIMS-ECTRIMS Global Meeting takes place October 21-24, 2023 in Toronto, Canada. Organized by European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Register now.

NEUROLOGY UPDATE Which kind of fatigue weighs most heavily in multiple sclerosis? Fatigue is among the most common and m...
21/09/2026

NEUROLOGY UPDATE

Which kind of fatigue weighs most heavily in multiple sclerosis?

Fatigue is among the most common and most disabling symptoms of MS, affecting up to 75 percent of patients and contributing to a poorer quality of life.

Looking at its dimensions separately, physical and psychosocial fatigue emerge as those with the greatest impact on health-related quality of life, which has implications for what is worth asking about in consultation.

Fatigue is one of the most common and debilitating symptoms of multiple sclerosis (MS); it affects up to 75% of MS patients and contributes to a poorer

CME OPPORTUNITYWhere does the treatment of Darier's disease currently stand?Darier's disease is a rare genodermatosis ca...
18/09/2026

CME OPPORTUNITY

Where does the treatment of Darier's disease currently stand?

Darier's disease is a rare genodermatosis caused by pathogenic variants in the ATP2A2 gene, following a chronic, relapsing course that usually begins in adolescence or early adulthood.

This CME update covers diagnosis and differential diagnosis, topical treatment with retinoids, corticosteroids and calcineurin inhibitors, and systemic therapy, where oral retinoids remain first-line for severe or refractory disease. It also looks at the emerging evidence for JAK inhibitors and biologics, and at physical and surgical options.

Darier's disease is caused by pathogenic variants in the ATP2A2 gene. Advances in our understanding of its pathophysiology have paved the way for the

Adresse

Neugasse 10
Zürich
8005

Benachrichtigungen

Erfahren Sie als Erste/r von Neuigkeiten und Aktionen: Wir schicken Ihnen eine E-Mail, wenn medizinonline.ch etwas veröffentlicht. Ihre E-Mail-Adresse wird für keinen anderen Zweck verwendet, und Sie können sich jederzeit abmelden.

Verknüpfungen

Teilen